The groups are worried about reduced competition if the merger goes through.
Remote monitoring should help doctors and patients identify issues earlier.
Sales of the treatment got off to a good start in the U.S., and Europe could follow suit.
The French drugmaker joins a host of other companies trying to develop vaccines and treatments for the coronavirus.
The government is also supporting the pharmaceutical giant's efforts to find a vaccine for the coronavirus.
The switch will increase the availability of pain and allergy drugs from GlaxoSmithKline and Alcon.
The COVID-19 virus is putting a wrinkle in the agency's activities.
A study finds an increased risk of cancer, and the manufacturer complies with the FDA's request.
It's gotten worse over the last 15 years.
The biotech could start testing its coronavirus vaccine as early as this summer.
A decision on the cancer therapy is expected by Aug. 17.
The drug moves closer to an expanded approval for the skin disorder.
A new report from the agency reviewed nearly 200 studies published on the subject over more than a decade.
A secondary offering causes dilution for the biotech.
Another win for the seeming unstoppable drug -- this time in metastatic triple-negative breast cancer.
The move would strip the Food and Drug Administration of the duty it's held for more than a decade.
The results were consistent with a pair of shorter studies of the combination treatment.
The company is starting a new clinical trial, but that may not be the only thing boosting the biotech's shares.
The move should be helpful as the DNA-sequencing specialist develops diagnostic tests that require his former agency's approval.
Rival GW Pharmaceuticals came out the big winner, as its competing seizure drug looks more effective.